What is Avela Health?
At Avela Health, our pediatric experts offer autism diagnostic evaluations and evidence-based naturalistic therapy scientifically proven to deliver outcomes. Our shared goal? Meaningful change, deep connections, and enduring joy. Together, we’ve got this.
Problem
The current situation for users is that traditionally diagnosing autism in children can be complicated and time-consuming. This often involves multiple consultations and inconsistent methodologies, which can delay getting an accurate diagnosis and starting effective treatment.
The drawbacks of the old situation include complicated and time-consuming diagnostics for autism, leading to delayed accurate diagnosis and treatment.
Solution
Avela Health offers a platform that provides expert autism care and diagnostics.
Pediatric experts offer autism diagnostic evaluations and evidence-based naturalistic therapy, which are scientifically proven to deliver meaningful outcomes.
Customers
Parents and guardians looking for effective autism diagnostic services for their children. They are likely to be involved in healthcare decision-making.
Demographics: Primarily parents of young children, healthcare advocates, and educators involved in early childhood development.
Pediatric healthcare professionals seeking effective diagnostic tools and therapies for autism.
Unique Features
Evidence-based naturalistic therapy.
Focus on meaningful change, deep connections, and enduring joy for families.
Combines diagnostic evaluations with therapy for comprehensive care.
User Comments
Users appreciate the expert-focused and evidence-based approach.
Parents find relief in the structured diagnostic process.
Therapies are seen as making a significant impact on the children's development.
Some users noted quick and reliable results.
Highly valued for providing holistic care.
Traction
A newly launched autism care platform.
Gaining attention for its expert-led evaluations and therapy services.
Reported early user satisfaction from parents.
Market Size
The global autism spectrum disorder treatment market was valued at $1.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.6% from 2021 to 2028.
